Table 6.
Polymeric Nanocarriers Obtained and Characterized in vivo for Delivery of Drugs Against Infectious Diseases
| Nanocarriers | Transporting Agent | Route of Administration | Animal Model | Application | Targeting |
|---|---|---|---|---|---|
| Eudragit L-100 nanocarriers164 | Curcumin | Orally | Healthy or Listeria monocytogenes-infected gerbils | Bacterial infection treatment | pH-sensitive |
| Cellulose acetate phthalate nanocarriers165 | Eugenol; Chlorhexidine | Orally | Healthy volunteers with periodontal disease | Bacterial infection treatment (periodontal disease) | pH-sensitive |
| PCL nanocarriers166 | Itraconazole | Topical application in the vagina | BALB/c mice inoculated intravaginally with Candida albicans | Fungal infection treatment (vulvovaginal candidiasis) | – |
| PLGA-PEG nanocarriers167–170 | Lychnopholide | Orally or i.v. | Healthy or Trypanosoma cruzi- infected Swiss mice; healthy C57BL/6 mice | Parasite infection treatment (Chagas disease) | – |
| PCL nanocarriers171 | Quercetin; penta-acetylated derivative of quercetin | Intragastric gavage | Leishmania amazonensis-infected BALB/c mice | Parasite infection treatment (Leishmaniasis) | – |
| Eudragit® RS100 or polysorbate 80 nanocarriers172 | Quinine | i.v. | Plasmodium berghei-infected Wistar rats | Parasite infection treatment (malaria) | – |
| Heparin nanocarriers173 | Artesunate | i.v. | Healthy BALB/c mice | Parasite infection treatment (malaria) | – |
| Polysorbate 80 nanocarriers or Eudragit® RS100 nanocarriers174,175 | Quinine; curcumin | i.p. | Wild-type N2 Bristol strain of Caenorhabditis elegans; Plasmodium berghei-infected Swiss mice | Parasite infection treatment (malaria) | – |
| PCL nanocarriers176 | Artemether | Orally | Healthy and Plasmodium berghei-infected C57BL/6 mice | Parasite infection treatment (malaria) | – |
Abbreviations: i.g., intragastric; i.p., intraperitoneal; i.v., intravenous; PCL, poly-e-caprolactone; PEG, poly(ethylene glycol); PLGA, poly(lactide-co-glycolide).